Investor Video Series: Discover the technology behind Occuity’s revolutionary optical platform - with CTO, Dr. Robin Taylor

Hi, I’m Robin, Co-founder and CTO at Occuity. I wanted to help you understand more about our technology platform, so I’ve made this short video to explain how it works and why it’s so central to what we do.

At Occuity, everything we create is built around a single, powerful idea — that the eye can tell us an extraordinary amount about our health.Our proprietary optical platform is what makes this possible. It’s the foundation of all our devices — from the PM1 Pachymeter to the AX1 Axiometer — and will power our future products, such as the SD1 Diabetes Screening Device and the Indigo Non-invasive Glucose Meter.

Our technology works by scanning light through the eye and analysing the light that returns. This allows us to measure the structures within the eye with great precision and to detect biomarkers that can provide insights into wider health — quickly, safely, and pain-free.

Because our approach is optical and non-contact, there’s no need to touch the eye and no consumables are required. That makes our devices simple and cost-effective for clinicians, and comfortable for patients.

One of our key goals — and something that really sets us apart — is to make advanced screening and diagnostic technology more accessible.All of our devices are hand-held, portable, and intuitive to use. You don’t need a dark room, a chin rest, or a specialist operator — just a quick scan that takes seconds.

By combining precision optics with innovative design, we’re creating clinical-grade instruments that can be used anywhere: in hospitals, optometry practices, community health settings, and even pharmacies.

Protecting our innovation is also an important part of our strategy. Through our platform approach, we’ve built what’s known as a patent thicket — a network of complementary patents that protects both our core technology and the products that integrate it.

We now have fifteen patent families, with fourteen granted and one pending, covering everything from optical design and scanning systems to alignment and data processing. This layered protection helps secure our position and creates strong barriers to entry for competitors.

We continue to innovate and expand our IP portfolio, with several new applications in draft and a wealth of deep in-house expertise that can’t easily be replicated.

It’s this combination — innovative design, broad capabilities, extensive expertise, and strong IP protection — that gives Occuity a real competitive edge.

Our optical platform isn’t just the basis for one product; it’s the foundation for an entire generation of non-contact, hand-held diagnostic devices.It’s how we’re unlocking the power of the eye to transform screening and diagnostics across global healthcare.

---

Occuity’s patented optical platform is opening up new possibilities in healthcare — and now, you can be part of that journey.Our Republic Europe crowdfunding round is live, giving you the chance to invest in our mission to transform how the world detects and monitors disease.👉 Invest in Occuity today

Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more: https://europe.republic.com/pages/risk-warnings